Prospects for a prophylactic HPV vaccine: Rationale and future implications for cervical cancer screening

Diagnostic Cytopathology

Volumn 18, Issue 1, 1998, Pages 5-9

  Sherman, Mark E ^a,b   Schiffman, Mark H ^b   Strickler, Howard ^b   Hildesheim, Allan ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervix; Cytology; Papillomavirus; Vaccine; VLP

Indexed keywords

CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; VIRUS DNA;

ARTICLE; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; SEXUAL TRANSMISSION; UTERINE CERVIX CANCER; WART VIRUS;

FEMALE; FORECASTING; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0031965314     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(199801)18:1<5::AID-DC2>3.0.CO;2-G     Document Type: Article

References (25)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. JNCI 1995;87:796-802.
2. Schiffman MH, Bauer HM, Hoover RN. et al. Epidemiologic evidence that human papillomavirus causes most cervical intraepithelial neoplasia. JNCI 1994;85:958-964
3. Crawford L. Prospects for cervical cancer vaccines. Cancer Surv 1993;16:215-229.
4. Hines JF, Ghim S, Schlegel R, Jenson AB. Review Prospects for a vaccine against human papillomavirus. Obstet Gynecol 1995;86:860-866.
5. Wu TC. Immunology of the human papillomavirus in relation to cancer. Curr Opin Immunol 1994;6:746-754.
6. Schiffman MH, Burk RD. Human papillomaviruses. In: Evans AS, Kaslow R, eds. Viral infections in humans. 4th ed. New York: Plenum Medical Book Company 1997: 983-1023.
7. Bosch FX, Castellsague X, Munoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. JNCI 1996;88:1060-1067.
8. Dillner J. Review. Serology of human papillomavirus Cancer J 1995;8:264-269.
9. Munger K, Schcffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumor suppressor gene products. Cancer Surv 1992;12:197-217.
10. Werness BA, Munger K, Howley PM. Role of human papillomavirus oncoproteins in transformation and carcinogenic progression. Important Adv Oncol 1991:3-18.
11. Kast WM, Feltkamp MCW, Ressing ME, Vierboom MPM, Brandt RMP, Melief CJM. Cellular immunity against human papillomavirus associated cervical cancer. Seminars in Virology 1996;7:117-123.
12. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991;352:723-725.
13. Lin Y, Borenstein LA, Sekvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992;187:612-619.
14. Lin Y, Borenstein LA, Ahmed R, Wettstein FO. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J Virol 1993;67:4154-4162.
15. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-3963.
16. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-965.
17. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996;713:314-320.
18. Jarrett WFH, Smith KT, O'Neil BW. et al. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 1991;184:33-42.
19. Kimbauer R, Chandrachud LM, O'Neil BW. et al. Virology 1996;219:37-44.
20. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WFH. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunisation. J Gen Virol 1993;74:945-953.
21. Bell JA, Sundberg JP, Ghim S, Newsome J, Jenson AB, Schlegel R. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 1994;62:194-198.
22. Suzich JA, Ghim S, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-11557.
23. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993;67:1936-1944.
24. Ostor A. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-192.
25. Schiffman MH, Manos MM, Sherman ME, Scott DR, Glass AG. Human papillomavirus and cervical intraepithelial neoplasia (letter). JNCI 1993;85:1868-1870.